Daniel Desgrandchamps

839 total citations
25 papers, 645 citations indexed

About

Daniel Desgrandchamps is a scholar working on Epidemiology, Health and Infectious Diseases. According to data from OpenAlex, Daniel Desgrandchamps has authored 25 papers receiving a total of 645 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 8 papers in Health and 5 papers in Infectious Diseases. Recurrent topics in Daniel Desgrandchamps's work include Vaccine Coverage and Hesitancy (8 papers), Viral gastroenteritis research and epidemiology (4 papers) and Influenza Virus Research Studies (4 papers). Daniel Desgrandchamps is often cited by papers focused on Vaccine Coverage and Hesitancy (8 papers), Viral gastroenteritis research and epidemiology (4 papers) and Influenza Virus Research Studies (4 papers). Daniel Desgrandchamps collaborates with scholars based in Switzerland, United States and Spain. Daniel Desgrandchamps's co-authors include Ulrich Heininger, U. B. Schaad, S. Suter, Hans Tegner, K. Ohlsson, F. A. Waldvogel, Shai Ashkenazi, Susanna Esposito, Timo Klemola and Bruce D. Forrest and has published in prestigious journals such as PEDIATRICS, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Daniel Desgrandchamps

23 papers receiving 610 citations

Peers

Countries citing papers authored by Daniel Desgrandchamps

Since Specialization

Citations

This map shows the geographic impact of Daniel Desgrandchamps's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Desgrandchamps with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Desgrandchamps more than expected).

Fields of papers citing papers by Daniel Desgrandchamps

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Desgrandchamps. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Desgrandchamps. The network helps show where Daniel Desgrandchamps may publish in the future.

Co-authorship network of co-authors of Daniel Desgrandchamps

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Desgrandchamps. A scholar is included among the top collaborators of Daniel Desgrandchamps based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Desgrandchamps. Daniel Desgrandchamps is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TBE in Switzerland and Liechtenstein 2023 ·Daniel Desgrandchamps, Klara M. Posfay‐Barbe	1
2	Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage 2018 ·The Journal of Clinical Pharmacology ·(unknown), Punnee Pitisuttithum, Nadia Tornieporth, Daniel Desgrandchamps, Flor M. Muñoz, Sonali Kochhar, Jim Buttery, Jorgen Bauwens, Jan Bonhoeffer	3
3	Interpretation of primary care physicians’ attitude regarding rotavirus immunisation using diffusion of innovation theories 2009 ·Vaccine ·Philipp Agyeman, Daniel Desgrandchamps, Bernard Vaudaux, Christoph Berger, Alessandro Diana, Ulrich Heininger, Claire‐Anne Siegrist, Christoph Aebi	11
4	Rotavirus vaccines: considerations for successful implementation in Europe 2006 ·The Lancet Infectious Diseases ·Pierre Van Damme, Marie Van der Wielen, Filippo Ansaldi, Daniel Desgrandchamps, Javier Díez‐Domingo, F. Giménez Sánchez, Jim Gray, (unknown), Kari Johansen, Paula Lorgelly, Mathie Lorrot, Nathalie Parez, (unknown), Markus A. Rose	35
5	Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections 2006 ·The Pediatric Infectious Disease Journal ·Shai Ashkenazi, André Vertruyen, (unknown), Susanna Esposito, (unknown), Timo Klemola, (unknown), (unknown), (unknown), Daniel Desgrandchamps, Sheau‐Mei Cheng, Jonathan R. Skinner, William C. Gruber, Bruce D. Forrest	231
6	Seroprevalence of Varicella-Zoster virus IgG antibodies in Swiss children during the first 16 months of age 2006 ·Vaccine ·Ulrich Heininger, Daniel Desgrandchamps, U. B. Schaad	41
7	Early Appearance of Bactericidal Antibodies after Polysaccharide Challenge of Toddlers Primed with a Group C Meningococcal Conjugate Vaccine: What Is Its Role in the Maintenance of Protection? 2006 ·Clinical and Vaccine Immunology ·Theodore F. Tsai, Ray Borrow, Hanspeter E. Gnehm, Bernard Vaudaux, Ulrich Heininger, Daniel Desgrandchamps, Christoph Aebi, Paul Balmer, Ronald Pedersen, Bernard Fritzell, Claire-Anne Siegrist	12
8	Guide sur les vaccinations: évidences et croyances... 2005 ·Bulletin des Médecins Suisses ·Claire‐Anne Siegrist, Christoph Aebi, Daniel Desgrandchamps, Ulrich Heininger, Bernard Vaudaux, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
9	How Do Physicians Immunize Their Own Children? Differences Among Pediatricians and Nonpediatricians 2005 ·PEDIATRICS ·Klara M. Posfay‐Barbe, Ulrich Heininger, Christoph Aebi, Daniel Desgrandchamps, Bernard Vaudaux, Claire‐Anne Siegrist	66
10	Seroprevalence of varicella-zoster virus immunoglobulin G antibodies in Swiss adolescents and risk factor analysis for seronegativity 2001 ·The Pediatric Infectious Disease Journal ·Ulrich Heininger, Charlotte Braun‐Fahrländer, Daniel Desgrandchamps, (unknown), Leticia Grize, Peter Wutzler, Urs B. Schaad, (unknown)	36
11	How to improve communication on vaccine issues at the national level? 2001 ·Vaccine ·Claire‐Anne Siegrist, Daniel Desgrandchamps, Ulrich Heininger, Bernard Vaudaux	13
12	Seroprävalenz von IgG-Antikörpern gegen Masern, Mumps und Röteln bei Schweizer Kindern in den ersten 16 Lebensmonaten 2000 ·Daniel Desgrandchamps, U. B. Schaad, (unknown), Guenter Tusch, Ulrich Heininger	1
13	[Herpes simplex virus type 1 and 2 in Switzerland]. 2000 ·PubMed ·Birgit Laubereau, Marcel Zwahlen, Beat Neuenschwander, Ulrich Heininger, Schaad Ub, Daniel Desgrandchamps	16
14	Die Impfung gegen Hepatitis B 1998 ·Sozial- und Präventivmedizin ·Daniel Desgrandchamps, Claire‐Anne Siegrist	0
15	Hepatitis-B-Impfung: Kenntnisse und Akzeptanz bei Schweizer Ärzten 1998 ·Sozial- und Präventivmedizin ·(unknown), Gary L. Freed, Daniel Desgrandchamps, Patrick Diebold	3
16	Vaccination contre l'hépatite B: Opinions et connaissances des médecins suisses 1998 ·Sozial- und Präventivmedizin ·(unknown), Gary L. Freed, Daniel Desgrandchamps, Patrick Diebold	1
17	The Swiss Paediatric Surveillance Unit (SPSU) 1995 ·Sozial- und Präventivmedizin ·H Zimmermann, Daniel Desgrandchamps, Gregor Schubiger	8
18	[Infectious gastroenteritis in the immunocompetent child. Significance of Cryptosporidium spp. and Aeromonas ssp]. 1989 ·PubMed ·Daniel Desgrandchamps, (unknown)	7
19	Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimens 1989 ·Antimicrobial Agents and Chemotherapy ·Daniel Desgrandchamps, (unknown)	9
20	Levels of Free Granulocyte Elastase in Bronchial Secretions from Patients with Cystic Fibrosis: Effect of Antimicrobial Treatment Against Pseudomonas aeruginosa 1986 ·The Journal of Infectious Diseases ·S. Suter, U. B. Schaad, Hans Tegner, K. Ohlsson, Daniel Desgrandchamps, F. A. Waldvogel	106

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact